Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MGCS: where do we stand today?
Iberri D, Liedtke M. Iberri D, et al. Among authors: liedtke m. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):482-488. doi: 10.1182/hematology.2024000572. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39644059 Free PMC article. Review.
Arbeitsbedingte Lärmexposition – wann besteht eine relevante Einwirkung?
Schneider G, Grap T, Liedtke M, Mahler B, Michel O, Römer W, Weisgerber F, Wolf U, Wolters I. Schneider G, et al. Among authors: liedtke m. Laryngorhinootologie. 2024 Nov;103(11):800-801. doi: 10.1055/a-2358-1817. Epub 2024 Nov 4. Laryngorhinootologie. 2024. PMID: 39496269 German. No abstract available.
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman K. Shah B, et al. Among authors: liedtke m. J Natl Compr Canc Netw. 2024 Oct;22(8):563-576. doi: 10.6004/jnccn.2024.0051. J Natl Compr Canc Netw. 2024. PMID: 39413812
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Muchtar E, et al. Among authors: liedtke m. JAMA Oncol. 2024 Oct 1;10(10):1362-1369. doi: 10.1001/jamaoncol.2024.2629. JAMA Oncol. 2024. PMID: 39088206
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Litzow MR, et al. Among authors: liedtke m. N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948. N Engl J Med. 2024. PMID: 39047240 Clinical Trial.
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. Srinagesh H, et al. Among authors: liedtke m. Blood. 2024 Oct 17;144(16):1689-1698. doi: 10.1182/blood.2024024952. Blood. 2024. PMID: 38968138 Clinical Trial.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Zhao Y, et al. Among authors: liedtke m. Blood Adv. 2024 Jun 25;8(12):3226-3236. doi: 10.1182/bloodadvances.2023012430. Blood Adv. 2024. PMID: 38607410 Free PMC article. Clinical Trial.
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Srinagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs A, Moon J, Baggott C, Arai S, Bharadwaj S, Johnston LJ, Liedtke M, Lowsky R, Meyer E, Negrin R, Rezvani A, Shizuru J, Sidana S, Egeler E, Mavroukakis S, Tunuguntla R, Gkitsas-Long N, Retherford A, Brown AK, Gramstrap-Petersen AL, Ibañez RM, Feldman SA, Miklos DB, Mackall CL, Davis KL, Frank M, Ramakrishna S, Muffly L. Schultz LM, et al. Among authors: liedtke m. Leukemia. 2024 May;38(5):963-968. doi: 10.1038/s41375-024-02220-y. Epub 2024 Mar 15. Leukemia. 2024. PMID: 38491306 Clinical Trial.
191 results